Genembryomics Announces Global Expansion Plans And Appointment Of Wallachbeth New York As Broker To A NASDAQ Stock Exchange Listing
By Julius Ewudo, ASEAN Region Representative
A medical genetics leader in pre-pregnancy genetic testing, GenEmbryomics has retained WallachBeth Capital as its financial advisor and investment banker to pursue a listing on a US stock exchange.
This strategic partnership unlocks opportunities for GenEmbryomics to access growth capital and expand globally. WallachBeth will advise GenEmbryomics on capital markets strategy and execution.
“We are thrilled to work with WallachBeth as we take this exciting next step,” said Chairman of GenEmbryomics Paul Viney. “Their expertise will be invaluable as we drive our mission to transform reproductive genetic testing worldwide.”
Founded in 2016, GenEmbryomics leverages proprietary technology to deliver the world’s first comprehensive whole genome sequencing tests for IVF embryos. This provides unmatched detection of over 4,500 genetic diseases, enabling optimal embryo selection for higher IVF success rates.
“Our revolutionary testing empowers families struggling with infertility to reduce the risk of passing genetic disorders to future children,” said CEO and Founder of GenEmbryomics, Dr. Nick Murphy. “Listing on a US exchange will accelerate growth and access for our life-changing innovations in the fertility field.”
GenEmbryomics’ s partnership with WallachBeth advances its goals of expanding globally and cementing its position as the leader in pre-pregnancy genetic screening.
